GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shuttle Pharmaceuticals Holdings SHPH · USD

Health Care · US listing · 🇺🇸 United States

Compare

5.19

-7.16%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Net income

−$11.7m

FY2014FY2025

Free cash flow

−$9.5m

FY2014FY2025

Shareholders' equity

$2.3m

FY2014FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017FY2014
Gross profit−$290,107−$5,463−$6,811−$5,972−$60,834−$54,951−$18,000−$18,739—
Research and development$4.1m$3.6m$3.5m$1.0m$1.0m$161,772$55,572$836$280,000
Operating income−$11.9m−$7.8m−$4.6m−$4.0m−$1.7m−$766,102−$586,630−$203,890−$330,000
Net income−$11.7m−$9.1m−$6.6m−$5.0m−$1.2m−$805,732−$626,139−$213,594−$330,000
Diluted earnings per share-57.91-22.43-4.10-3.67-0.85-0.79-0.62-0.21-1.33

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017FY2014
Total assets$10.5m$2.5m$6.0m$8.7m$651,641$544,047$621,275$121,298$250,000
Cash and short-term investments$334,005$1.9m$5.5m$8.4m$504,749$117,153$352,390$50,709$110,000
Total liabilities$8.2m$1.8m$1.9m$975,676$2.3m$2.2m$593,819$405,646$10,000
Debt$232,147$1.2m$1.1m$748,296$978,877$874,285$400,000$314,377—
Shareholders' equity$2.3m$709,152$4.1m$7.7m−$1.6m−$1.7m$27,456−$284,348$240,000
Shares outstanding0m0m2m1m1m1m1m1m—

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2018FY2017FY2014
Cash from operations−$9.5m−$7.3m−$5.6m−$2.7m−$300,336−$26,831−$566,692−$202,705−$330,000
Capital spending−$5−$19,046−$19,046—−$4−$10,818−$10,818——
Free cash flow−$9.5m−$7.3m−$5.6m−$2.7m−$300,340−$37,649−$577,510−$202,705−$330,000
Dividends paid———−$402,068—————

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue——————$5,748—
Gross profit—−$633,340−$289,070−$1,008—−$1,008−$1,796−$793
Operating income−$3.9m−$2.2m−$2.8m−$2.3m−$3.9m−$3.0m−$1.8m−$3.5m
Net income−$3.1m−$2.2m−$2.6m−$2.3m−$3.7m−$3.1m−$1.6m−$3.8m
Diluted earnings per share-3.10-2.12-12.92-11.60-18.31-15.08-3.92-9.28
Cash from operations—−$2.0m—−$2.0m−$3.0m−$2.0m−$2.0m−$1.0m
Total assets$22.8m$11.8m$10.5m$3.5m$5.5m$5.3m$2.5m$673,568
Cash and short-term investments$90,238$1.1m$334,005$2.1m$4.8m$4.5m$1.9m$156,656
Debt$82,811$79,962$77,194$492,013$517,822$884,084$935,384$308,652
Shareholders' equity$19.2m$3.3m$2.3m$1.4m$3.6m$3.3m$709,152−$1.3m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income43.6%73.1%43.1%
Net income32.9%70.8%42.9%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-0.3-9.6-221.8-1067.3

Share price return

Finished calendar years

2025202420232022
Return-89%-85%-78%-80%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 11 Jun 2026
  • 25-to-1 reverse split · 16 Jun 2025
  • 8-to-1 reverse split · 13 Aug 2024

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.